Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s

Executive Summary

The launch of generic rosuvastatin offers yet another way to calculate the disappointing performance of the PCSK9 inhibitors.


Related Content

AstraZeneca CEO Says Post-Crestor Future On Track As Pipeline Builds
Crestor Generics To Launch After 12-Day Delay
'No Meaningful Change' In Pricing Environment, Teva Says
AZ Crows About Oncology Portfolio In 1Q; Strives For $1.1bn Cost Save
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha
Lilly's Evacetrapib Raises More Doubts For HDL Theory
Amgen's Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors
UnitedHealth's Oxford Group Picks Praluent As First-Line PCSK9
Teva to buy Allergan Generics; Mylan off the hook but Perrigo still wriggling
AstraZeneca gives Actavis generic Crestor head start


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts